Cited by 149Mitochondrial Function and PathologyMetabolism and Genetic DisordersAdipose Tissue and Metabolism

Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models

Open access
Komen, J C, Thorburn, D R·2014·British Journal of Pharmacology

Abstract

The oxidative phosphorylation (OXPHOS) system in mitochondria is responsible for the generation of the majority of cellular energy in the form of ATP. Patients with genetic OXPHOS disorders form the largest group of inborn errors of metabolism. Unfortunately, there is still a lack of efficient therapies for these disorders other than management of symptoms. Developing therapies has been complicated because, although the total group of OXPHOS patients is relatively large, there is enormous clinical and genetic heterogeneity within this patient population. Thus there has been a lot of interest in generating relevant mouse models for the different kinds of OXPHOS disorders. The most common treatment strategies tested in these mouse models have aimed to up-regulate mitochondrial biogenesis, in order to increase the residual OXPHOS activity present in affected animals and thereby to ameliorate the energy deficiency. Drugs such as bezafibrate, resveratrol and AICAR target the master regulator of mitochondrial biogenesis PGC-1α either directly or indirectly to manipulate mitochondrial metabolism. This review will summarize the outcome of preclinical treatment trials with these drugs in mouse models of OXPHOS disorders and discuss similar treatments in a number of mouse models of common diseases in which pathology is closely linked to mitochondrial dysfunction. In the majority of these studies the pharmacological activation of the PGC-1α axis shows true potential as therapy; however, other effects besides mitochondrial biogenesis may be contributing to this as well.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12413

Cites

188 of 188 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AICAR rescued mitochondrial function in mice deficient in cytochrome c oxidase and augmented exercise endurance in healthy animals in a PGC1α-dependent manner, even if they were untrained.

    “AICAR also rescued mitochondrial function in mice deficient in cytochrome c oxidase and augmented exercise endurance in healthy animals in a PGC1α-dependent manner, even if they were untrained (255, 256).”
  • In insulin-deficient mice, bezafibrate improves impaired glucose metabolism by augmenting hepatic mitochondrial performance, suppressing hepatic inflammatory pathways, and improving insulin sensitivity.

    “In insulin-deficient mice, bezafibrate improves impaired glucose metabolism by augmenting hepatic mitochondrial performance [reviewed in Komen and Thorburn (255)], suppressing hepatic inflammatory pathways, and improving insulin sensitivity (271).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

5 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Komen, J. C., & Thorburn, D. R.
Affiliations
Royal Children's Hospital (AU)
Corresponding author
Thorburn, D R
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2014-03-28
Volume
171
Issue
8
Pages
1818-1836
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1903564790
Cited by
149
References
188
Citations by year
2026: 7 · 2025: 12 · 2024: 13 · 2023: 6 · 2022: 13 · 2021: 15 · 2020: 17 · 2019: 13 · 2018: 17 · 2017: 11 · 2016: 8 · 2015: 11 · 2014: 6
FWCI
0.78
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Australian National Health and Medical Research Council
  • Victorian Government�s Operational Infrastructure Support Program
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
mitochondrial biogenesis, PGC-1α, oxidative phosphorylation disorders, inborn errors of metabolism, bezafibrate, resveratrol, AICAR, mitochondrial dysfunction, mouse model, pharmacological activation, energy deficiency
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Resveratrol, Aminoimidazole Carboxamide, Animals, Bezafibrate, Disease Models, Animal, Energy Metabolism, Mitochondria, Ribonucleotides, Stilbenes, Transcription Factors, Up-Regulation, Mitochondrial Diseases, AMP-Activated Protein Kinases, Sirtuin 1, Mitochondrial Turnover

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review